Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tony Thayanandan

I am an experienced Clinical Trial Manager currently completing a DPhil in Psychiatry at the University of Oxford, supervised by Professors Clare Mackay and Vanessa Raymont. The principal objective of my DPhil is to understand whether a history of mild Traumatic Brain Injury (mTBI) creates vulnerability to neurodegeneration or accelerates existing changes in mid to early late-life in participants at risk of Alzheimer's Disease (AD).

I am also the Trial Manager for the Deep and Frequent Phenotyping (DFP) study, which aims to create a comprehensive database of different measures taken from people at risk of Alzheimer's disease. This includes regular brain scans, cognitive and memory tests, retinal imaging, blood tests, and wearable technology to measure movement, gait, and ongoing cognitive abilities. The DFP study, run from within DPUK and led by Prof. Vanessa Raymont, is the world's most detailed study into preclinical AD, recruiting participants across the UK.

With a strong background in neurodegeneration and neuroimaging analysis, I have led the planning and execution of multiple clinical trials, ensuring adherence to protocols, regulatory compliance, and successful project delivery. I hold an MSc in Research Methods in Clinical Psychology and a BSc in Psychology, and I am committed to making significant contributions to the field of neurodegenerative research.